150 completed, 55 unknown, 28 recruiting, 11 terminated. 70 Not applicable, 60 Phase 2, 29 Phase 3, 19 Phase 1, 16 Phase 4.
Follow University of Cologne: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stratification and Treatment in Early Psychosis Study -ASSIST CBD 100 mg/mL Oral Solution, Placeb - Treatment Resistant Psychosis, Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 250 | 2027-01-01 | 2026-10-08 |
| A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC) Tarlatamab, Carboplatin, Etoposid - Extensive Disease Small Cell Lung Cancer | Phase 2 | Not yet recruiting | University of Cologne | 54 | 2026-11-01 | 2026-07-13 |
| Artificial Intelligence - Based Opportunistic Coronary Artery Calcium Scoring on Routine Chest-CT Scan Coronary Artery Calcification, Cardiovascular Risk | Not yet recruiting | University of Cologne | 1950 | 2026-11-01 | 2026-09-09 | |
| Stratification and Treatment in Early Psychosis Study - ENHANCE CBD 100 mg/mL Oral Solution, Placebo - Psychosis, First Episode Psychosis | Phase 3 | Recruiting | University of Oxford | 250 | 2026-10-05 | 2026-10-08 |
| Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients mid-frequency whole-body electromyostimulation (WB-EMS), conventional exercise training, nutritional therapy - Oesophageal Cancer, Gastric Cancer | Not applicable | Not yet recruiting | University of Cologne | 88 | 2026-08-01 | 2026-07-27 |
| Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology. Partially-standardised, supervised, continuity-of-care exercise intervention - Pediatric Cancer Patients | Not applicable | Recruiting | Universität Duisburg-Essen | 346 | 2026-07-01 | 2026-09-11 |
| Artificial Intelligence(AI) in the Emergency Department (ED) in Cologne Emergency Care, Clinical Decision Support | Active not recruiting | University of Cologne | 100000 | 2026-07-01 | 2026-07-28 | |
| FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis FEEL GOOD, Treatment as Usual (TAU) - Delusional Disorder, Brief Psychotic Disorder | Not applicable | Recruiting | Stephanie Mehl | 252 | 2026-05-27 | 2026-09-22 |
| Prevention-in-PD-Study Multidomain lifestyle intervention - Parkinson's Disease (PD) | Not applicable | Recruiting | University Hospital Schleswig-Holstein | 99 | 2026-04-01 | 2026-10-15 |
| STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease Dapagliflozin 10 mg, Matching Placebo - Polycystic Kidney, Autosomal Dominant | Phase 3 | Recruiting | University of Cologne | 420 | 2025-12-16 | 2026-07-28 |
| Trial of a Voice-Based Generative AI Emotional Support Companion The intervention was the AI-based emotional support app., Psychoeducational Material - Anxiety and Fear | Not applicable | Completed | University of Cologne | 400 | 2025-11-14 | 2026-10-06 |
| VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle TRE: Time-restricted eating - Vaccination, Immunosenescence | Not applicable | Recruiting | Charite University, Berlin, Germany | 24 | 2025-09-10 | 2025-09-18 |
| Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Not yet recruiting | University of Cologne | 40 | 2025-08-01 | 2025-04-06 |
| Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma BrECADD - Hodgkin Lymphoma (Category) | Phase 2 | Not yet recruiting | University of Cologne | 35 | 2025-08-01 | 2025-04-09 |
| Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab - Immunotherapy, HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Michael Dill | 48 | 2025-07-16 | 2025-08-06 |
| Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma Pembrolizumab - Classical Hodgkin Lymphoma | Phase 2 | Not yet recruiting | University of Cologne | 50 | 2025-06-01 | 2025-04-08 |
| Vaccine-induced Immunity in Immunocompromised Patients Immunodeficiency | Recruiting | University of Cologne | 1000 | 2025-03-25 | 2026-05-12 | |
| Clostridioides Difficile Controlled Human Infection Model encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin - C. Difficile, C. Difficile Infection | Not applicable | Not yet recruiting | Leiden University Medical Center | 60 | 2025-03-01 | 2024-11-22 |
| Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy Intervention group /arm 1 (Cataract surgery alone), Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK) - Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy | Not applicable | Recruiting | University of Cologne | 120 | 2025-01-24 | 2025-02-21 |
| Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Syndrome in Patients With Profound Hyponatremia in the Emergency Department Hyponatremia | Completed | University of Cologne | 1000 | 2024-11-01 | 2026-04-30 |
Showing 20 of 261. Sign in to see all of them.
Hodgkin Disease (18) · Schizophrenia (14) · Psychotic Disorders (10) · Premature Birth (7) · Hyponatremia (6) · Neoplasms (6) · Acute Kidney Injury (5) · Lymphoma, Non-Hodgkin (5) · Attention Deficit Disorder with Hyperactivity (4) · COVID-19 (4) · Carcinoma, Non-Small-Cell Lung (4) · Coronary Artery Disease (4) · Lymphoma (4) · Motor Activity (4) · Polycystic Kidney, Autosomal Dominant (4)
Doxorubicin (13) · Cyclophosphamide (11) · Dacarbazine (8) · Prednisone (8) · Bleomycin (7) · Etoposide (7) · Vinblastine (7) · Vincristine (6) · Procarbazine (5) · Rituximab (5) · Bevacizumab (4) · Brentuximab Vedotin (4) · Everolimus (4) · pembrolizumab (4) · Amisulpride (3)
Germany (233) · Spain (9) · Netherlands (8) · Italy (5) · United Kingdom (5) · Switzerland (3) · United States (3) · Austria (2) · France (2) · Greece (2) · Israel (2) · Belgium (1) · Bulgaria (1) · China (1) · Denmark (1)
Volker Burst, MD (11) · Andreas Engert, Prof. (9) · Andreas Engert (5) · Peter Borchmann, Prof. (5) · Maria Vehreschild, MD (3) · Oliver A Cornely, MD (3) · Oliver A. Cornely, MD (3) · Volker Diehl, Prof. (3) · Wolfgang Gaebel, Professor (3) · Anja Goertz-Dorten, PhD (2) · Christof Scheid, Prof. Dr. (2) · Eckhard Schoenau, Prof. (2) · F. Markus Leweke, MD (2) · Fikret Er, MD (2)
PMID 40135712, PMID 30010775, PMID 41074963, PMID 23509310, PMID 24121121, PMID 32719417, PMID 34473343, PMID 39588126, PMID 39636474, PMID 42379221, PMID 10882162, PMID 12165894, PMID 12880954, PMID 15337804, PMID 16129365, PMID 17488673, PMID 17609490, PMID 17934748, PMID 18052570, PMID 20305034, PMID 20525999, PMID 20551376, PMID 20565956, PMID 20624316, PMID 20673559, PMID 20713848, PMID 20818855, PMID 21382172, PMID 21828141, PMID 21844497, PMID 21901296, PMID 21911573, PMID 21917759, PMID 21986981, PMID 21990399, PMID 22008088, PMID 22075649, PMID 22169408, PMID 22456770, PMID 22584787, PMID 22735306, PMID 22869884, PMID 22926606, PMID 23013513, PMID 23225085, PMID 23335740, PMID 23544125, PMID 23736089, PMID 24023786, PMID 24385516
2005 (4), 2025 (3), 2008 (2), 2009 (2), 2014 (2), 2015 (2), 2018 (2), 2019 (2), 2016 (1)